ELI LILLY & Co

The company discovers, develops, manufactures, and markets human pharmaceutical products within a single business segment. It manufactures and distributes its products from facilities located in the United States, including Puerto Rico, as well as in Europe and Asia. The company sells its products in approximately 90 countries. Its product portfolio includes treatments across various therapeutic areas. In Cardiometabolic Health, products include Basaglar, a long-acting human insulin analog for diabetes, developed in collaboration with Boehringer Ingelheim. Other diabetes treatments are Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, and insulin lispro mix 75/25, which are human insulin analogs. Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 are human insulins of recombinant DNA origin for diabetes. Jardiance, also in collaboration with Boehringer Ingelheim, treats type 2 diabetes, reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, reduces the risk of cardiovascular death and hospitalizations for heart failure in adults, and reduces the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. Mounjaro is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist for adults with type 2 diabetes, used with diet and exercise to improve glycemic control. Trulicity treats type 2 diabetes in adults and pediatric patients 10 years and older, and reduces the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.